New combo therapy may save kidneys in High-Risk urinary tract cancer

This study tests a two-drug treatment (gemcitabine and a gel form of mitomycin called Jelmyto) for people with a high-risk but favorable type of upper urinary tract cancer. The goal is to see if this combination can destroy the cancer while preserving the kidney, avoiding the standard surgery that removes the kidney and ureter. About 28 adults with non-invasive tumors will receive the drugs in sequence through a tube into the kidney. The main measure of success is whether the cancer completely disappears after treatment.